Emboldened by strong data for its oral IL-23 inhibitor icotrokinra in psoriasis, Johnson & Johnson has said it will see if it can outperform its big-selling injectable therapy Stelara in a head-to ...

It was better than Stelara in reaching PASI 90 and IGA 0/1 at that timepoint, and also topped placebo on the more stringent PASI 100 and IGA 0 measures, which represent completely clear skin.

Johnson & Johnson (J&J) has announced that Stelara (ustekinumab) has been approved by the European Commission (EC) to treat moderately to severely active Crohn’s disease (CD) in paediatric patients.

Otulfi is FDA-approved for subcutaneous and intravenous formulations to treat the same conditions as Stelara (ustekinumab), including Crohn’s disease, ulcerative colitis, moderate to severe ...